Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30094147 | 1.00 | KMT2A (0.59) | KMT2AEPHX2SMN1; SMN2LMNAFABP7 | |
| SCHEMBL4556421 | 1.00 | KMT2A (0.59) | KMT2AEPHX2SMN1; SMN2LMNAFABP7 | |
| SCHEMBL19050989 | 1.00 | KMT2A (0.59) | KMT2AEPHX2SMN1; SMN2LMNAFABP7 | |
| SCHEMBL4557536 | 1.00 | KMT2A (0.59) | KMT2AEPHX2SMN1; SMN2LMNAFABP7 | |
| SCHEMBL31548843 | 1.00 | KMT2A (0.59) | KMT2AEPHX2SMN1; SMN2LMNAFABP7 | |
| SCHEMBL20173568 | 1.00 | KMT2A (0.59) | KMT2AEPHX2SMN1; SMN2LMNAFABP7 | |
| SCHEMBL13671094 | 1.00 | KMT2A (0.59) | KMT2AEPHX2SMN1; SMN2LMNAFABP7 | |
| SCHEMBL4557033 | 1.00 | KMT2A (0.59) | KMT2AEPHX2SMN1; SMN2LMNAFABP7 | |
| SCHEMBL1782935 | 0.99 | KMT2A (0.60) | KMT2AEPHX2SMN1; SMN2LMNAFABP7 | |
| SCHEMBL31010196 | 0.93 | KMT2A (0.60) | KMT2AEPHX2SMN1; SMN2LMNAFABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3125943-B1 | PHOSPHATE BASED LINKERS FOR INTRACELLULAR DELIVERY OF DRUG CONJUGATES | MERCK SHARP & DOHME LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20230099074-A1 | ANTIBODY DRUG CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS | MERCK SHARP & DOHME LLC (US) | 2023-03-30 | — | — | US | disclosed |
| US-11510993-B2 | Antibody drug conjugate for anti-inflammatory applications | MERCK SHARP & DOHME LLC (US) | 2022-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11510993-B2 | Antibody drug conjugate for anti-inflammatory applications | CD44, FCGR2A, TNF | KMT2A 4262/4885EPHX2 615/4885SMN1; SMN2 3451/4885 |
| US-20230099074-A1 | ANTIBODY DRUG CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS | CD44, FCGR2A, TNF | KMT2A 4262/4885EPHX2 615/4885SMN1; SMN2 3451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.